Minas P Economides1, Srdan Verstovsek2, Naveen Pemmaraju3. 1. Department of Internal Medicine, The University of Texas School of Health Sciences at Houston, Houston, TX, USA. 2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. 3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. npemmaraju@mdanderson.org.
Abstract
PURPOSE OF REVIEW: With increased understanding of the pathobiology of myeloproliferative neoplasms (MPNs), multiple new agents are now being investigated. We aim to cover some of the current treatment options for MPNs and discuss new agents in development. RECENT FINDINGS: The introduction of ruxolitinib improved the treatment of many patients with intermediate and higher risk myelofibrosis. However, ruxolitinib monotherapy does not benefit all patients, and not all patients can receive this therapy due to limiting cytopenias. The unraveling of new molecular abnormalities and cellular pathways led to the development of several novel targeted agents that are currently under investigation in clinical trials. These agents have different mechanisms of action and are being used either alone or in combination with ruxolitinib. Novel targets include inhibition of apoptosis, the tumor microenvironment, telomerase enzyme action, immunotherapy, and fibrosis with associated cytokines. We comprehensively review and summarize the available preclinical and clinical trials with novel agents for MPNs.
PURPOSE OF REVIEW: With increased understanding of the pathobiology of myeloproliferative neoplasms (MPNs), multiple new agents are now being investigated. We aim to cover some of the current treatment options for MPNs and discuss new agents in development. RECENT FINDINGS: The introduction of ruxolitinib improved the treatment of many patients with intermediate and higher risk myelofibrosis. However, ruxolitinib monotherapy does not benefit all patients, and not all patients can receive this therapy due to limiting cytopenias. The unraveling of new molecular abnormalities and cellular pathways led to the development of several novel targeted agents that are currently under investigation in clinical trials. These agents have different mechanisms of action and are being used either alone or in combination with ruxolitinib. Novel targets include inhibition of apoptosis, the tumor microenvironment, telomerase enzyme action, immunotherapy, and fibrosis with associated cytokines. We comprehensively review and summarize the available preclinical and clinical trials with novel agents for MPNs.
Entities:
Keywords:
JAK inhibitors; Myeloproliferative neoplasms; Novel drugs; Novel therapies; Ruxolitinib
Authors: Adam J Mead; Dragana Milojkovic; Steven Knapper; Mamta Garg; Joseph Chacko; Mira Farquharson; John Yin; Sahra Ali; Richard E Clark; Chris Andrews; Meryem Ktiouet Dawson; Claire Harrison Journal: Br J Haematol Date: 2015-03-30 Impact factor: 6.998
Authors: Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker Journal: Nature Date: 2005-04-28 Impact factor: 49.962
Authors: Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg Journal: Nature Date: 2005-05-15 Impact factor: 49.962
Authors: E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green Journal: Lancet Date: 2005 Mar 19-25 Impact factor: 79.321
Authors: Claire N Harrison; Adam J Mead; Anesh Panchal; Sonia Fox; Christina Yap; Emmanouela Gbandi; Aimee Houlton; Samah Alimam; Joanne Ewing; Marion Wood; Frederick Chen; Jason Coppell; Nicki Panoskaltsis; Steven Knapper; Sahra Ali; Angela Hamblin; Robyn Scherber; Amylou C Dueck; Nicholas C P Cross; Ruben Mesa; Mary Frances McMullin Journal: Blood Date: 2017-08-09 Impact factor: 22.113
Authors: Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine Journal: PLoS Med Date: 2006-07 Impact factor: 11.069
Authors: Soraya Carrancio; Jennifer Markovics; Piu Wong; Jim Leisten; Paola Castiglioni; Matthew C Groza; Heather K Raymon; Carla Heise; Tom Daniel; Rajesh Chopra; Victoria Sung Journal: Br J Haematol Date: 2014-03-18 Impact factor: 6.998
Authors: Steven De Almeida; Mathilde Regimbeau; Gaëtan Jego; Carmen Garrido; François Girodon; François Hermetet Journal: Cancers (Basel) Date: 2020-09-11 Impact factor: 6.639
Authors: Krisstina Gowin; Blake T Langlais; Heidi E Kosiorek; Amylou Dueck; Denise Millstine; Jennifer Huberty; Ryan Eckert; Ruben A Mesa Journal: Cancer Med Date: 2020-11-03 Impact factor: 4.452